A Phase 2a study of oral ZPL-3893787 in adults with plaque psoriasis
Research type
Research Study
Full title
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.
IRAS ID
192418
Contact name
Aliya Asher
Contact email
Sponsor organisation
Ziarco Pharma Ltd
Eudract number
2015-003812-19
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Psoriasis is a chronic, inflammatory skin disease which can be difficult to treat.
ZPL3893787-18 is a an oral drug which selectively blocks histamine H4 receptors. Pre-clinical data suggests that blocking H4 in patients with psoriasis could reduce the inflammation and itch associated with the condition.
This study will be conducted in dedicated research centres in England. Adult patients with moderate to severe psoriasis will receive study medication for 12 weeks and total study participation will be approx. 19 weeks.
The study is expected to last 1 year.
The study will aim to recruit 120 patients and will be carried out in approx. 20 sites in 4 countries. It is expected that approximately 50 patients will be recruited in the UK.REC name
South Central - Oxford B Research Ethics Committee
REC reference
15/SC/0660
Date of REC Opinion
4 Dec 2015
REC opinion
Further Information Favourable Opinion